DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trialSilvio Danese, Gert Van Assche, B E Sands et al.|Journal of Crohn s and Colitis|2019Cited by 8
P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFIB E Sands, William J. Sandborn, Laurent Peyrin‐Biroulet et al.|Journal of Crohn s and Colitis|2019Cited by 5
833a – Efficacy in Biologic-Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderatesevere Ulcerative Colitis: UnifiBruce E. Sands, William J. Sandborn, Laurent Peyrin‐Biroulet et al.|Gastroenterology|2019Cited by 3
689 Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction TrialBruce E. Sands, Silvio Danese, David Rowbotham et al.|The American Journal of Gastroenterology|2019Cited by 3
DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extensionWilliam J. Sandborn, Silvio Danese, David Rowbotham et al.|Journal of Crohn s and Colitis|2020Cited by 3